Video
Dr. Cookson on darolutamide data: “An exciting move forward”
Author(s):
“This concept of adding additional therapy early on is ready for primetime,” says Michael S. Cookson, MD, MMHC.
In this video, Michael S. Cookson, MD, MMHC, shares insights from the study, “Darolutamide in combination with androgen-deprivation therapy and docetaxel for metastatic hormone-sensitive prostate cancer: overall survival and other outcomes of the phase 3 ARASENS trial,” which will be presented at the 2022 South Central Section of the AUA Annual Meeting in Coronado, California. professor and chair of urology at the University of Oklahoma Health Sciences Center in Oklahoma City, is co-editor in chief of Urology Times.®
Related Videos
Related Content
